Avalo Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2022 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Avalo Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2022 to Q2 2023.
  • Avalo Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending June 30, 2023 was $38K.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Period Value YoY Chg Change % Date Report Filed
Q2 2023 $38K Jun 30, 2023 10-Q 2023-08-03
Q4 2022 $0 Dec 31, 2022 10-Q 2023-08-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.